Market News & Trends
Acer Therapeutics & Relief Therapeutics Announce FDA Acceptance for Filing of NDA
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics Holding SA recently announced the US FDA has accepted for filing the New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for the….
Timber Pharmaceuticals Reports Positive Top-Line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate-to-Severe Congenital Ichthyosis
Timber Pharmaceuticals, Inc. recently announced positive top-line data from its Phase 2b CONTROL study evaluating TMB-001, an investigational topical isotretinoin formulated using Timber's patented IPEG…
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals, Strengthening its CNS Product Portfolio
Supernus Pharmaceuticals, Inc. and Adamas Pharmaceuticals, Inc. recently announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share…
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
Pacira BioSciences, Inc. and Flexion Therapeutics, Inc. recently announced a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash,…
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca
Fortress Biotech, Inc. and a company it founded, Caelum Biosciences, Inc. recently announced the closing of AstraZeneca’s acquisition of Caelum, pursuant to the Development, Option…
Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of Monoclonal Antibody
Acumen Pharmaceuticals, Inc. recently announced dosing of the first patient in INTERCEPT-AD, the Phase 1 placebo-controlled, single- and multiple-dose clinical trial of ACU193, a monoclonal…
Albireo Announces Exclusive Licensing Agreement With Jadeite Medicines
Albireo Pharma, Inc. recently entered into an exclusive licensing agreement with Jadeite Medicines, Inc. for the development and commercialization of Bylvay (odevixibat) in Japan for…
Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis
Processa Pharmaceuticals, Inc. recently announced it has been cleared by the US FDA to proceed with a Phase 2a clinical trial of PCS12852 in patients…
Agenus to Receive $20-Million Milestone Payment From Bristol Myers Squibb With Dosing of First Patient
Agenus Inc. recently announced it has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb for AGEN1777, an Fc-enhanced bispecific….
Metrics Contract Services Enters Partnership to Develop Oncology Drug
Metrics Contract Services, the US-based contract pharmaceutical development and manufacturing division of Mayne Pharma, recently announced the signing of a development and manufacturing agreement with….
MilliporeSigma Launches Excipient Technology Platform for Viscosity Reduction of Protein-Based Therapeutics
MilliporeSigma has recently launched a new Viscosity Reduction Excipient Platform to reduce the viscosity and help overcome manufacturing and formulation challenges associated with….
MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza in Pediatric Population
MannKind Corporation recently announced the enrollment of the first pediatric patient in the INHALE-1 study. The multi-center study will evaluate the efficacy and safety of….
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
InMed Pharmaceuticals Inc. recently announced it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time….
Avacta Group Announces Achievement of Preclinical Development Milestone in LG Chem Life Sciences Partnership
Avacta Group plc recently announced a preclinical development milestone has been achieved in the multi-target therapeutics development partnership with LG Chem Life Sciences, the life sciences division of the South Korean LG Group, triggering an….
Boehringer Ingelheim & OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in Combination With Anti-PD-1 Antibody Ezabenlimab, in Patients With Advanced Endometrium or Colorectal Tumors
Boehringer Ingelheim and OSE Immunotherapeutics SA recently announced that the first patient has been dosed in the expansion phase of the Phase 1 clinical trial…
Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders Through Research Collaboration With Mayo Clinic
Castle Creek Biosciences, Inc. recently announced a research collaboration with Mayo Clinic to advance discovery and preclinical development of investigational gene therapy candidates for the…
Adaptive Biotechnologies Launches Enhanced clonoSEQ Assay Reports for Patients With Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status
Adaptive Biotechnologies Corporation recently announced the launch of an enhanced version of its clonoSEQ B-cell Clonality (ID) report, which will now feature the immunoglobulin heavy…
Starton Therapeutics Announces Successful Results in STAR-LLD Toxicology Study: No Myelosuppression & Excellent Tolerability
Starton Therapeutics Inc. recently announced the results of a preclinical toxicology study for STAR-LLD. STAR-LLD is a continuous delivery system of lenalidomide in development for…
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, & Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
Minerva Neurosciences, Inc. recently announced results from a pivotal bioequivalence study comparing the roluperidone formulations used in its late-stage Phase 2b and Phase 3 trials,…
Catalent Opens New Full-Service Clinical Supply Facility in Shiga, Japan
Catalent recently announced the opening of its new clinical supply facility, strategically located in the Shiga prefecture of Japan, in response to increased demand for…
